

Hikma completes Xellia acquisition

London, 10 September 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today announces that it has completed its acquisition of Xellia Pharmaceuticals' US finished dosage form (FDF) business and related assets following clearance under applicable US antitrust laws. The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D center in Zagreb, Croatia. Hikma has paid cash consideration of 135 million (subject to customary adjustments), with additional contingent consideration of up to 50 million payable upon achievement of certain regulatory and commercial milestones.

Transaction highlights:

- Supports the long-term growth of Hikma's Injectables business
- Diversifies and enriches Hikma's US injectables portfolio and pipeline
- Expands Hikma's high-quality manufacturing capacity
- Adds complex manufacturing technologies
- Enhances Hikma's R&D capabilities
- Neutral to Group core earnings in the first 12 months following closing and accretive thereafter, with meaningful longer-term benefits

Dr Bill Larkins, President, Injectables commented:

"This acquisition adds significant scale to our US operations and enhances our US injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term."

-- ENDS -

Enquiries:

Hikma (Investors)

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 (0)7776 477050
Guy Featherstone Director, Investor Relations	+44 (0)20 3892 4389/ +44 (0)7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 (0)7970 709912

Press

Teneo - Doug Campbell / Rob Yates	+44 (0)7753 136628/ +44 (0)7715 375443
Hikma - Steve Weiss	+1-732-788-8279

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them

customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQFLFLTALIAIS